SCYNEXIS INC (SCYX)
US8112922005 - Common Stock
Overall SCYX gets a fundamental rating of 2 out of 10. We evaluated SCYX against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SCYX have multiple concerns. SCYX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year SCYX has reported negative net income.
SCYX had a negative operating cash flow in the past year.
SCYX had negative earnings in 4 of the past 5 years.
In the past 5 years SCYX reported 4 times negative operating cash flow.
1.2 Ratios
SCYX's Return On Assets of -36.79% is in line compared to the rest of the industry. SCYX outperforms 48.96% of its industry peers.
Looking at the Return On Equity, with a value of -62.26%, SCYX is in line with its industry, outperforming 48.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.79% | ||
| ROE | -62.26% | ||
| ROIC | N/A |
ROA(3y)-15.59%
ROA(5y)-38.9%
ROE(3y)-650.17%
ROE(5y)-521.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for SCYX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SCYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SCYX has more shares outstanding
Compared to 5 years ago, SCYX has more shares outstanding
The debt/assets ratio for SCYX has been reduced compared to a year ago.
2.2 Solvency
SCYX has an Altman-Z score of -5.58. This is a bad value and indicates that SCYX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SCYX (-5.58) is worse than 67.19% of its industry peers.
A Debt/Equity ratio of 0.23 indicates that SCYX is not too dependend on debt financing.
SCYX's Debt to Equity ratio of 0.23 is in line compared to the rest of the industry. SCYX outperforms 42.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.58 |
ROIC/WACCN/A
WACC10.14%
2.3 Liquidity
SCYX has a Current Ratio of 3.13. This indicates that SCYX is financially healthy and has no problem in meeting its short term obligations.
SCYX has a Current ratio (3.13) which is comparable to the rest of the industry.
SCYX has a Quick Ratio of 3.13. This indicates that SCYX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.13, SCYX perfoms like the industry average, outperforming 55.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.13 | ||
| Quick Ratio | 3.13 |
3. Growth
3.1 Past
The earnings per share for SCYX have decreased strongly by -155.22% in the last year.
The Revenue for SCYX has decreased by -93.70% in the past year. This is quite bad
SCYX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 251.82% yearly.
EPS 1Y (TTM)-155.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)-93.7%
Revenue growth 3YN/A
Revenue growth 5Y251.82%
Sales Q2Q%-100%
3.2 Future
The Earnings Per Share is expected to decrease by -14.25% on average over the next years. This is quite bad
The Revenue is expected to decrease by -10.49% on average over the next years. This is quite bad
EPS Next Y-135.35%
EPS Next 2Y-67.7%
EPS Next 3Y-1.84%
EPS Next 5Y-14.25%
Revenue Next Year-86.83%
Revenue Next 2Y-43.12%
Revenue Next 3Y-5.8%
Revenue Next 5Y-10.49%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
SCYX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 8.64, the valuation of SCYX can be described as reasonable.
SCYX's Price/Forward Earnings ratio is rather cheap when compared to the industry. SCYX is cheaper than 89.58% of the companies in the same industry.
SCYX is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.82, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 8.64 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-67.7%
EPS Next 3Y-1.84%
5. Dividend
5.1 Amount
No dividends for SCYX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SCYNEXIS INC
NASDAQ:SCYX (11/21/2024, 8:00:02 PM)
After market: 1.1607 -0.03 (-2.46%)1.19
+0.01 (+0.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap45.16M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 8.64 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.79% | ||
| ROE | -62.26% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.13 | ||
| Quick Ratio | 3.13 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-155.22%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-135.35%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-93.7%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y